rood blauwe elepsis logo Belegger.nl

Accsys krijgt maximaal 2,5 miljoen per jaar van Solvay bij productie van 63.000 m3

12 Posts
| Omlaag ↓
  1. forum rang 10 DeZwarteRidder 25 maart 2015 00:05
    This licence agreement grants Solvay the exclusive rights for 15 years to produce and sell Accoya within about 40 European countries, whist the Netherlands, Belgium, Luxemburg, UK and Ireland remain territories of Accsys. The first constructed plant has a capacity of 63,000 m³ Accoya output and Solvay has an option on more plants. Accsys will receive licence and royalty fees, building up to about EUR 2.5m per annum when nearing full capacity.
  2. forum rang 10 DeZwarteRidder 25 maart 2015 00:07
    tull 31 dec 2013 om 13:33:
    ----------------------------
    Research Morning Notes for 23/12/2013
    Accsys: Breakthrough: First fully effective licence agreement

    Accsys (Buy): Breakthrough: First fully effective licence agreement
    The facts: Accsys announced that the board of Solvay has formally approved the licence agreement for Accoya, reflecting the starting signal for the construction of the first licence plant for Accoya.
    Our analysis: Accsys's strategy focuses on two revenue streams, the first is the production of Accoya in its plant in Arnhem and the second is revenue streams from multiple licence agreements for both Accoya and Tricoya.
    Growth momentum of Accoya is strong, fuelled by increasing industry recognition and further market penetration. In the first half of the current book year ending 3/2014 the company reported 62% growth in sales to Accoya customers. We expect Accsys's production plant in Arnhem to be EBITDA positive this year now that the break-even level of 17,500 m³ has been surpassed. The company as a whole is expected to be EBITDA positive in fiscal year 3/2016.
    Accsys aims to maximise the global use of Accoya and Tricoya through licensing its technology. Until now there wasn't any licence plant operational. The Solvay licence is therefore a very important breakthrough for the company following several (optional) licence agreements, which didn't result in the construction of a licence plant, such as the one with Diamond Wood.
    This licence agreement grants Solvay the exclusive rights for 15 years to produce and sell Accoya within about 40 European countries, whist the Netherlands, Belgium, Luxemburg, UK and Ireland remain territories of Accsys. The first constructed plant has a capacity of 63,000 m³ Accoya output and Solvay has an option on more plants. Accsys will receive licence and royalty fees, building up to about EUR 2.5m per annum when nearing full capacity.
    New to the agreement is that Solvay is exploring possibilities of constructing the plant on Accsys's land in Arnhem instead of in Freiburg, Germany, in order to create economies of scale. On top of that, the companies are exploring coordinated operational and maintenance services for both companies in Arnhem, which could offer Accsys another stream of income. Although both these factors increase the eventual value of the Solvay licence, it also means a delay in construction of the plant of about 3 months. The first production is now expected early 2016, by which time the company's Arnhem plant could have already reached the stage of full capacity.
    The Solvay licence could have a positive impact on the market with more companies possibly following suit. Currently, Accsys has a conditional licence agreement for Tricoya with Medite. Approval from the board is expected mid-2014 with the plant fully operational early 2016. Accsys is currently in early conversations with several potential licence partners for both Accoya and Tricoya.
    Our Base Case scenario takes into account the production at Accsys's own production plant, the Solvay licence agreement and the conditional agreement with Medite (attaching 50% success rate). We have made a separate valuation for the Solvay license, which adds EUR 0.04 to Accsys DCF value. Previously we attached a success rate of 80% to this license into our DCF model. We raise our price target from EUR 0.19 to EUR 0.20 to incorporate the now fully unconditional licence agreement with Solvay.
    The Optimistic scenario anticipates multiple license agreements such as the Solvay one, which hints on a potential value of EUR 0.30.
    Conclusion & Action: The fully effective Solvay licence agreement is a very important breakthrough for the company as this signals the start of the second stream of income next to the revenues from the production plant in Arnhem. We raise our price target to EUR 0.20 and maintain our Buy rating.
  3. [verwijderd] 25 maart 2015 08:00
    quote:

    DeZwarteRidder schreef op 25 maart 2015 00:07:

    tull 31 dec 2013 om 13:33:
    ----------------------------
    Research Morning Notes for 23/12/2013
    Accsys: Breakthrough: First fully effective licence agreement

    Accsys (Buy): Breakthrough: First fully effective licence agreement
    The facts: Accsys announced that the board of Solvay has formally approved the licence agreement for Accoya, reflecting the starting signal for the construction of the first licence plant for Accoya.
    Our analysis: Accsys's strategy focuses on two revenue streams, the first is the production of Accoya in its plant in Arnhem and the second is revenue streams from multiple licence agreements for both Accoya and Tricoya.
    Growth momentum of Accoya is strong, fuelled by increasing industry recognition and further market penetration. In the first half of the current book year ending 3/2014 the company reported 62% growth in sales to Accoya customers. We expect Accsys's production plant in Arnhem to be EBITDA positive this year now that the break-even level of 17,500 m³ has been surpassed. The company as a whole is expected to be EBITDA positive in fiscal year 3/2016.
    Accsys aims to maximise the global use of Accoya and Tricoya through licensing its technology. Until now there wasn't any licence plant operational. The Solvay licence is therefore a very important breakthrough for the company following several (optional) licence agreements, which didn't result in the construction of a licence plant, such as the one with Diamond Wood.
    This licence agreement grants Solvay the exclusive rights for 15 years to produce and sell Accoya within about 40 European countries, whist the Netherlands, Belgium, Luxemburg, UK and Ireland remain territories of Accsys. The first constructed plant has a capacity of 63,000 m³ Accoya output and Solvay has an option on more plants. Accsys will receive licence and royalty fees, building up to about EUR 2.5m per annum when nearing full capacity.
    New to the agreement is that Solvay is exploring possibilities of constructing the plant on Accsys's land in Arnhem instead of in Freiburg, Germany, in order to create economies of scale. On top of that, the companies are exploring coordinated operational and maintenance services for both companies in Arnhem, which could offer Accsys another stream of income. Although both these factors increase the eventual value of the Solvay licence, it also means a delay in construction of the plant of about 3 months. The first production is now expected early 2016, by which time the company's Arnhem plant could have already reached the stage of full capacity.
    The Solvay licence could have a positive impact on the market with more companies possibly following suit. Currently, Accsys has a conditional licence agreement for Tricoya with Medite. Approval from the board is expected mid-2014 with the plant fully operational early 2016. Accsys is currently in early conversations with several potential licence partners for both Accoya and Tricoya.
    Our Base Case scenario takes into account the production at Accsys's own production plant, the Solvay licence agreement and the conditional agreement with Medite (attaching 50% success rate). We have made a separate valuation for the Solvay license, which adds EUR 0.04 to Accsys DCF value. Previously we attached a success rate of 80% to this license into our DCF model. We raise our price target from EUR 0.19 to EUR 0.20 to incorporate the now fully unconditional licence agreement with Solvay.
    The Optimistic scenario anticipates multiple license agreements such as the Solvay one, which hints on a potential value of EUR 0.30.
    Conclusion & Action: The fully effective Solvay licence agreement is a very important breakthrough for the company as this signals the start of the second stream of income next to the revenues from the production plant in Arnhem. We raise our price target to EUR 0.20 and maintain our Buy rating.
    Dank je Zwarte Ridder.
  4. mjmj 25 maart 2015 10:52
    quote:

    DeZwarteRidder schreef op 25 maart 2015 00:07:

    tull 31 dec 2013 om 13:33:

    The Optimistic scenario anticipates multiple license agreements such as the Solvay one, which hints on a potential value of EUR 0.30.
    Conclusion & Action: The fully effective Solvay licence agreement is a very important breakthrough for the company as this signals the start of the second stream of income next to the revenues from the production plant in Arnhem. We raise our price target to EUR 0.20 and maintain our Buy rating.
    hoe is het met die fabriek in Arnhem?

    de omgekeerde spit was 5 op 1? dus 0,20 pence = 1 pond? (ca 1,40 euro?)
  5. machmit 25 maart 2015 11:56
    quote:

    mjmj schreef op 25 maart 2015 10:52:

    [...]

    hoe is het met die fabriek in Arnhem?

    de omgekeerde spit was 5 op 1? dus 0,20 pence = 1 pond? (ca 1,40 euro?)
    Goed dat je het bericht van de Zwarte Ridder nog even aanvult.
  6. torbu 25 maart 2015 13:47
    quote:

    mjmj schreef op 25 maart 2015 12:59:

    .. de antwoorden op de vragen die ik stelde?
    "Arnhem",draait op volledige capaciteit.

    Split was 0,20 euro.
  7. mjmj 25 maart 2015 14:44
    Ok thx! Is de capaciteit de laatste jaren uitgebreid of zijn er plannen om dat te doen (getuige het hierboven aangehaalde persbericht)
  8. torbu 25 maart 2015 15:07
    quote:

    mjmj schreef op 25 maart 2015 14:44:

    Ok thx! Is de capaciteit de laatste jaren uitgebreid of zijn er plannen om dat te doen (getuige het hierboven aangehaalde persbericht)
    Arnhem zit zo goed als aan zijn max.
    Freiburg moet in 2016 lucht gaan verschaffen.
    Als er meer (mogelijk) is,hoor ik dat ook graag!
  9. mjmj 25 maart 2015 15:38
    Is Freiburg dan in de kaarten? In het persbericht wordt gerept over opschaling van Arnhem in plaats van een nieuwe fabriek in Freiburg.
  10. [verwijderd] 26 maart 2015 02:39
    mjmj

    Deze fabriek wordt momenteel in Freiburg gebouwd en gaat beginnen met produktie beging 2016.

    Google dit dan vind je de inductrial area waar dit is, strategies gelegen aan een railway hub.

    Tijdens het bouwen zijn er zogenaamde mijlstone betalingen en de eerst is al betaald door Solvay in het derde kwartaal meen ik me te herinneren.

    This licence agreement grants Solvay the exclusive rights for 15 years to produce and sell Accoya within about 40 European countries, whist the Netherlands, Belgium, Luxemburg, UK and Ireland remain territories of Accsys. The first constructed plant has a capacity of 63,000 m³ Accoya output and Solvay has an option on more plants. Accsys will receive licence and royalty fees, building up to about EUR 2.5m per annum when nearing full capacity.

    Cheers!
12 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.070
AB InBev 2 5.521
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.740
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.753
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.754
Aedifica 3 917
Aegon 3.258 322.877
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.894
Agfa-Gevaert 14 2.051
Ahold 3.538 74.340
Air France - KLM 1.025 35.079
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.923
Allfunds Group 4 1.479
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.358
AMG 971 133.689
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.017
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.785
Arcelor Mittal 2.034 320.766
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.251
ASML 1.766 108.025
ASR Nederland 21 4.501
ATAI Life Sciences 1 7
Atenor Group 1 507
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.684
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.404